[go: up one dir, main page]

AR036329A1 - Compuesto derivado de tiazol, imidazol y oxazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento - Google Patents

Compuesto derivado de tiazol, imidazol y oxazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento

Info

Publication number
AR036329A1
AR036329A1 ARP020101330A ARP020101330A AR036329A1 AR 036329 A1 AR036329 A1 AR 036329A1 AR P020101330 A ARP020101330 A AR P020101330A AR P020101330 A ARP020101330 A AR P020101330A AR 036329 A1 AR036329 A1 AR 036329A1
Authority
AR
Argentina
Prior art keywords
thiazol
methyl
butyl
tert
imidazol
Prior art date
Application number
ARP020101330A
Other languages
English (en)
Inventor
Jeremiah Harnett
Dennis Bigg
Anne-Marie Liberatore
Alain Rolland
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0104943A external-priority patent/FR2823208B1/fr
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR036329A1 publication Critical patent/AR036329A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuesto derivado de tiazol, imidazol y oxazol, seleccionado entre los siguientes compuestos: 2,6-di-ter-butil-4-{2-[2-(metilamino)etil]-1,3-tiazol-4-il}fenol; 2,6-di-ter-butil-4-[4-(hidroximetil)-1,3-oxazol-2-il]fenol; 2,6-di-ter-butil-4-{2-[1-(metilamino)etil]-1,3-tiazol-4-il}fenol; 2,6-di-ter-butil-4-[2-(metoximetil)-1,3-tiazol-4-il]fenol; 2,6-di-ter-butil-4-{4-[(metilamino)metil]-1,3-oxazol-2-il}fenol; N-{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}acetamida; [4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il] metilcarbamato de etilo; 2,6-di-ter-butil-4-[2-(morfolin-4-ilmetil)-1,3-tiazol-4-il]fenol; 2,6-di-ter-butil-4-[2-(tiomorfolin-4-ilmetil)-1,3-tiazol-4-il]fenol; 4-[2-(anilinometil)-1,3-tiazol-4-il]-2,6-di-ter-butilfenol; 2,6-di-ter-butil-4-(2-{[[2-(dimetilamino)etil](metil)amino]metil}-1,3-tiazol4-il)fenol; 2,6-di-ter-butil-4-{5-metil-2-[(metilamino)metil]-1,3-tiazol-4-il}fenol; 1-[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metanamina; N{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}N-metilacetamida; 1-[4-(3,5-di-ter-butil-4-metoxifenil)-1,3-tiazol-2-il]-N-metilmetanamina; 2,6-di-ter-butil-4-{2-[(etilamino)metil]-1,3-tiazol-4-il}fenol; 2,6-di-ter-butil-4-{2-[(4-fenilpiperazin-1-il)metil]-1,3-tiazol-4-il}-fenol; 2,6-di-ter-butil-4-{2-[(4-metil-1,4-diazepan-1-il)metil]-1,3-tiazol-4-il}fenol; N-{1-[4-(4-anilinofenil)-1,3-tiazol-2-il]etil}-N-metilamina; 2,6-di-ter-butil-4-{2-[(isopropilamino)metil]-1,3-tiazol-4-il}fenol; 2,6-di-ter-butil-4-{2-[(ciclohexilamino)metil]-1,3-tiazol-4-il-fenol; 2,6-di-ter-butil-4-{2-[(4-isopropilpiperazin-1-il)metil]-1,3-tiazol-4-il}fenol; N-metil-1-[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]etanamina; 2,6-di-ter-butil-4-{2-[(4-etilpiperazin-1-il)metil]-1,3-tiazol-4-il}fenol; N{[4-(4-anilinofenil)-1,3-tiazol-2-il]metil}-N-etilamina; N-{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metil}etanamina; 2,6-di-ter-butil-4-(2-{[4-(dimetilamino)piperidin-1-il]metil}-1,3-tiazol4-il)fenol; 1-{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}piperidin-4-ol; 2-[4-(1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de 4-metilpentilo; 2-[4-(4-pirrolidin-1-ilfenil)-1H-imidazol-2-il]etilcarbamato de 3,3-dimetilbutilo; 2-[4-(1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de isopentilo; 2-[4-(4'-bromo-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de hexilo; 2-[4-(4-ter-butilfenil)-1H-imidazol-2-il]etilcarbamato de bencilo; 2-[4-(1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de 3,3-dimetilbutilo; 2-[4-(4-pirrolidin-1-ilfenil)-1H-imidazol-2-il]etilcarbamato de hexilo; 2-[4-(3,5-di-ter-butil-4-hidroxifenil)-1H-imidazol-2-il]etilcarbamato de hexilo; 2-[4-(3,5-di-ter-butil-4-hidroxifenil)-1H-imidazol-2-il]etilcarbamato de 3,3-dimetilbutilo; 2-[4-(4-metoxifenil)-1H-imidazol-2-il]etilcarbamato de 3,3-dimetilbutilo; 2-[4-(3,5-di-ter-butil-4-hidroxifenil)-1H-imidazol-2-il]etilcarbamato de bencilo; 2-[4-(4-pirrolidin-1-ilfenil)-1H-imidazol-2-il]etilcarbamato de bencilo; 2-[4-(1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de 2-feniletilo; 2-[4-(4'-fluoro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(1,1'-bifenil-4-il)-5-metil-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(4'-metil-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(4'-cloro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(2'-fluoro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(2',4'-difluoro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2,6-di-ter-butil-4-{2-[(propilamino)metil]-1,3-tiazol-4-il}fenol; N-{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metil}-N-propilamina; N-{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metil}butan-1-amina; N-{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metil}pentan-1-amina; 1-{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}piperidin-3-ol; 1-{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}pirrolidin-3-ol; [4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metanol; N,N-dimetil-N-{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il] metil}amina; 2-{2-[(4-metilpiperazin-1-il)metil]-1,3-tiazol-4-il}-10H-fenotiazina; 2-[2-(piperidin-1-ilmetil)-1,3-tiazol-4-il]-10H-fenotiazina; 2-[2-(piperazin-1-ilmetil)-1,3-tiazol-4-il]-10H-fenotiazina; 1-{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}azetidin-3-ol; 2-[2-(morfolin-4-ilmetil)-1,3-tiazol-4-il]-10H-fenotiazina; 2-[2-(tiomorfolin-4-ilmetil)-1,3-tiazol-4-il]-10H-fenotiazina; 2-{2-[(4-metil-1,4-diazepan-1-il)metil]-1,3-tiazol-4-il}-10H-fenotiazina; (3R)-1-{[4-(3, 5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il] metil}pirrolidin-3-ol; (3S)-1-{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}pirrolidin-3-ol; 2,6-di-ter-butil-4-[2-(pirrolidin-1-ilmetil)-1,3-tiazol-4-il]fenol; 2,6-di-ter-butil-4-{2-[(butilamino)metil]-1,3-tiazol-4-il}fenol; 2-{2-[(4-etilpiperazin-1-il)metil]-1,3-tiazol-4-il}-10H-fenotiazina; N-metil-N-{[4-(10H-fenotiazin-2-il)-1H-imidazol-2-il]metil}amina; [4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metilcarbamato de metilo; [4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metilcarbamato de butilo; N-neopentil-N-{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metil}amina; 1-{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metil}piperidin-4-ol; N-{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metil}acetamida; N-{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metil}butanamida; 2,6-di-ter-butil-4-{2-[(4-propilpiperazin-1-il)metil]-1,3-tiazol-4-il}fenol; 2,6-di-ter-butil-4-{2-[2-metil-1-(metilamino)propil]-1,3-tiazol-4-il}fenol; N,2-dimetil-1-[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]propan-1-amina; N{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metil}hexanamida; (3R)-1-{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metil}pirrolidin-3-ol; (3S)-1-{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metil}pirrolidin-3-ol; 1-{[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]metil}azetidin-3-ol; 2-{2-[(4-propilpiperazin-1-il)metil]-1,3-tiazol-4-il}-10H-fenotiazina; 2-{2-[(4-acetilpiperazin-1-il)metil]-1,3-tiazol-4-il}-10H-fenotiazina; 2-{2-[(4-butilpiperazin-1-il)metil]-1,3-tiazol-4-il}-10H-fenotiazina; 4-[{[4-(10H-fenotiazin-2-il)-1 3-tiazol-2-il]metil}piperazin-1-carboxilato de metilo; 4-[2-(aminometil)-1H-imidazol-4-il]-2,6-di-ter-butilfenol; 4-{2-[(bencilamino)metil]-1,3-tiazol-4-il}-2,6-di-ter-butilfenol; 4-{2-[(4-acetilpiperazin-1-il)metil]-1,3-tiazol-4-il}-2,6-di-ter-butilfenol; N-metil-N-{[4-(10H-fenoxazin-2-il)-1,3-tiazol-2-il]metil}amina; 4-[2-(azetidin-1-ilmetil)-1,3-tiazol-4-il]-2,6-di-ter-butilfenol; 2,6-di-ter-butil-4-{2-[(4-butilpiperazin-1-il)-metil]-1,3-tiazol-4-il}-fenol; 2-[4-(3'-cloro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(3'-fluoro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(4-isobutilfenil)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(4-isobutilfenil)-1H-imidazol-2-il]etilcarbamato de bencilo; 2-[4-(3'-cloro-4'-fluoro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(3',4'-dicloro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(4-propilfenil)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(4-etilfenil)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(4'-ciano-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(1,1'-bifenil-4-il)-5-etil-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(2'-cloro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(2',3'-difluoro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(2'-bromo-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(3',5'-difluoro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(2'-metoxi-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(3'-nitro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(2',5'-difluoro-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 2-[4-(3'-metoxi-1,1'-bifenil-4-il)-1H-imidazol-2-il]etilcarbamato de butilo; 4-{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}piperazin-1-carboxilato de metilo; [4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metilcarbamato de metilo; N-{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}benzamida; N{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}-2-fenilacetamida; N{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}propanamida; acetato de 1-{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol2-il]metil}piperidin-4-ilo; 1-{[4-(3,5-di-ter-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}pirrolidina-3,4-diol; o una sal de dicho compuesto. Los compuestos y las composiciones farmacéuticas que los comprenden, presentan por lo menos una de las siguientes actividades farmacológicas: inhibición de las monoamina oxidasas (MAO), inhibición de la peroxidación lipídica, modulación de los canales de sodio. Como resultado de sus propiedades farmacológicas, dichos compuestos pueden ser utilizados en particular para fabricar medicamentos para tratar los siguientes trastornos o enfermedades: enfermedad de Parkinson, demencia senil, mal de Alzheimer, Corea de Huntington, esclerosis amiotrófica lateral, esquizofrenia, depresiones, psicosis, migrana o dolores y en particular dolores neuropáticos.
ARP020101330A 2001-04-10 2002-04-10 Compuesto derivado de tiazol, imidazol y oxazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento AR036329A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104943A FR2823208B1 (fr) 2001-04-10 2001-04-10 Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments
FR0201811 2002-02-14

Publications (1)

Publication Number Publication Date
AR036329A1 true AR036329A1 (es) 2004-09-01

Family

ID=26212970

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101330A AR036329A1 (es) 2001-04-10 2002-04-10 Compuesto derivado de tiazol, imidazol y oxazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento

Country Status (22)

Country Link
EP (1) EP1379514B1 (es)
JP (1) JP4422964B2 (es)
KR (1) KR100865809B1 (es)
CN (1) CN1284777C (es)
AR (1) AR036329A1 (es)
AU (1) AU2002307980B2 (es)
BR (2) BR0208703A (es)
CA (1) CA2443403C (es)
CZ (1) CZ304550B6 (es)
DE (1) DE60232959D1 (es)
ES (1) ES2328467T3 (es)
HU (1) HU228192B1 (es)
IL (2) IL158121A0 (es)
IS (1) IS2724B (es)
MX (1) MXPA03009194A (es)
MY (1) MY142094A (es)
NO (1) NO326051B1 (es)
NZ (1) NZ528645A (es)
PL (1) PL211939B1 (es)
RU (1) RU2288224C2 (es)
TW (1) TWI248438B (es)
WO (1) WO2002083656A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI292316B (en) 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
WO2004089918A1 (ja) * 2003-04-09 2004-10-21 Japan Tobacco Inc. 複素芳香５員環化合物及びその医薬用途
PT1470818E (pt) * 2003-04-25 2006-11-30 Neuro3D Utilização de derivados de fenotiazina piperazina no fabrico de um medicamento com efeitos neuroprotectores e/ou neurotróficos no cns e/ou pns
FR2888116A1 (fr) 2005-07-08 2007-01-12 Sod Conseils Rech Applic Derives de thiazoles pour traiter les dyskinesies
EP1806819A1 (en) * 2006-01-05 2007-07-11 Constructions Electroniques + Telecommunications, en abrégé "C.E.+T" Backup power system
TW200848417A (en) * 2007-02-22 2008-12-16 Organon Nv Indole derivatives
MD20140037A2 (ro) * 2011-10-26 2014-08-31 Pfizer Limited Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu
CN113831360A (zh) * 2021-09-10 2021-12-24 中钢集团南京新材料研究院有限公司 酰胺邻位导向硼化合成1-咔唑-硼酸频哪醇酯的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
CN1088062C (zh) * 1994-11-23 2002-07-24 纽罗根公司 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
US5843975A (en) * 1995-06-02 1998-12-01 Synthelabo Oxazolidinone derivatives, their preparation and therapeutical use
US5969146A (en) * 1995-10-11 1999-10-19 Synthelabo Oxazolidin-2-one derivatives, preparation method therefor and therapeutical use thereof
JP2001505585A (ja) * 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
FR2764889B1 (fr) * 1997-06-20 2000-09-01 Sod Conseils Rech Applic Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
CN1281442A (zh) * 1997-10-06 2001-01-24 伊莱利利公司 用作神经保护剂的新颖化合物
DE69904595T2 (de) * 1998-06-12 2003-11-27 Societe De Conseils De Recherches Et D'applications Scientifiques S.A., Paris Betacarbolinverbindungen
KR20020015308A (ko) * 1999-03-26 2002-02-27 추후보정 아릴 치환된 피라졸, 이미다졸, 옥사졸, 티아졸 및 피롤,및 이의 용도
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof

Also Published As

Publication number Publication date
NO326051B1 (no) 2008-09-08
KR100865809B1 (ko) 2008-10-28
ES2328467T3 (es) 2009-11-13
WO2002083656A3 (fr) 2003-01-03
CZ20033054A3 (cs) 2004-05-12
IL158121A0 (en) 2004-03-28
EP1379514A2 (fr) 2004-01-14
CA2443403A1 (fr) 2002-10-24
RU2003132471A (ru) 2005-01-27
NZ528645A (en) 2004-11-26
BRPI0208703B1 (pt) 2017-12-12
IL158121A (en) 2010-04-15
PL372297A1 (en) 2005-07-11
CZ304550B6 (cs) 2014-07-02
HUP0303799A3 (en) 2008-03-28
CN1535267A (zh) 2004-10-06
MXPA03009194A (es) 2004-02-17
TWI248438B (en) 2006-02-01
BR0208703A (pt) 2006-02-21
MY142094A (en) 2010-09-15
HU228192B1 (en) 2013-01-28
DE60232959D1 (de) 2009-08-27
HK1070055A1 (en) 2005-06-10
CA2443403C (fr) 2011-09-20
IS6979A (is) 2003-10-08
RU2288224C2 (ru) 2006-11-27
JP4422964B2 (ja) 2010-03-03
HUP0303799A2 (hu) 2004-03-01
WO2002083656A2 (fr) 2002-10-24
CN1284777C (zh) 2006-11-15
PL211939B1 (pl) 2012-07-31
IS2724B (is) 2011-03-15
JP2004531526A (ja) 2004-10-14
NO20034524L (no) 2003-10-29
EP1379514B1 (fr) 2009-07-15
AU2002307980B2 (en) 2007-06-21
NO20034524D0 (no) 2003-10-09
KR20030094333A (ko) 2003-12-11

Similar Documents

Publication Publication Date Title
EA201000196A1 (ru) Кристаллическая форма дигидрохлорида метил((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((метоксикарбонил)амино)-3-метилбутаноил)-2-пирролидинил)-1н-имидазол-5-ил)-4-бифенилил)-1н-имидазол-2-ил)-1-пирролидинил)карбонил)-2-метилпропил)карбамата
AR036329A1 (es) Compuesto derivado de tiazol, imidazol y oxazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento
AR029006A1 (es) Derivados de heterociclos con 5 miembros, su preparacion y su uso como medicamentos
NZ598441A (en) Boron-containing small molecules
BRPI0415424A (pt) processo para preparação de composto de aminocrotonila
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
AR037996A1 (es) Compuesto derivado de amino nicotinato, composicion farmaceutica; proceso para su preparacion y su uso como medicamento
PE20091042A1 (es) Ligandos de oxadiazol del receptor metabotropico del glutamato y su uso como potenciadores - 841
BR0016424A (pt) Inibidores de n-[5-[[[5-alquiil-2-oxazolil]metil]-tio]-2-tiazolil]carbox amida de cinases dependentes de ciclina
NZ594981A (en) Hepatitis c virus inhibitors
LU92146I2 (fr) Dasatinib et ses sels pharmaceutiquement acceptables
BR0012804A (pt) Derivados de amina e amida como ligandos para o receptor de neuropeptìdeo y y5 útil no tratamento da obesidade e outros distúrbios
KR900016121A (ko) 소염제 및 퇴화 억제제로서 유용한 치환된 아제티디논
EA200200975A1 (ru) Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси] бензил]тиазолидин-2,4-диона
AR057753A2 (es) Derivados de quinazolina, proceso para su preparacion y composiciones farmaceuticas que los contienen
DE602004018386D1 (de) Verfahren zur herstellung von 4-(2-dipropylaminoethyl)-1,3-dihydro-2h-indol-2-on-hydrochlorid
RU2015112192A (ru) 2-оксо-2,3,4,5-тетрагидро-1н-бензо[b]диазепины и их применение при лечении рака
PE20020917A1 (es) Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato
BR0308146A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
AR054214A1 (es) Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c.
WO2010006234A3 (en) Anticancer oral formulation
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
PE20061373A1 (es) Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida
MX2022007499A (es) Compuestos adhesivos fotoprotectores y usos de los mismos.
MA31742B1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FG Grant, registration